SCHEMBL1995456

SCHEMBL1995456

CC(C)CN1C(=O)CN(Cc2ccc(-c3ccc(F)c(CN4CCOCC4)c3)cc2)C1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.41
HRH3 Q9Y5N1 2/20 0.41
KCNH2 Q12809 3/20 0.40
CYP2A13 Q16696 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
ATM Q13315 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
CHEK1 O14757 2/20 0.37
ENPP2 Q13822 1/20 0.37
HSD17B10 Q99714 1/20 0.37
HTR2A P28223 1/20 0.36
GRM2 Q14416 1/20 0.36
NMT1 P30419 1/20 0.36
HDAC1 Q13547 1/20 0.35
HDAC2 Q92769 1/20 0.35
HDAC8 Q9BY41 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HTR1A P08908 1/20 0.35
DRD2 P14416 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1997243 0.90 HRH3 (0.44) HRH3ENPP2NMT1HDAC1HDAC2
SCHEMBL2001890 0.88 KMT2A (0.37) HRH3ENPP2HTR2AGRM2NMT1
SCHEMBL2000696 0.87 WDR5 (0.41) HRH3
SCHEMBL1995051 0.83 ADORA2A (0.39) HRH3KCNH2CYP2A13
SCHEMBL1998644 0.83 METAP2 (0.43) HRH3KCNH2CYP2A13ENPP2GRM2
SCHEMBL1998349 0.83 ENPP2 (0.48) LRRK2HRH3KCNH2CYP2A13NPC1
SCHEMBL1998519 0.77 CYP2A13 (0.42) HRH3CYP2A13NPC1RAB9AATM
SCHEMBL839667 0.77 CXCR4 (0.44) HRH3ENPP2HDAC6HTR1ADRD2
SCHEMBL1997193 0.75 HRH3 (0.46) HRH3ENPP2CYP2D6CYP2C19
SCHEMBL1998795 0.75 CYP2D6 (0.49) HRH3ENPP2NMT1HDAC6CYP2D6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US claimed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US claimed
EP-2373627-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. Organon (NL) 2011-10-12 EP disclosed
US-7960560-B2 1-(biphenyl-4-ylmethyl)imidazolidine-2,4-dione N.V. ORGANON (NL) 2011-06-14 US disclosed
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE N. V. ORGANON 2010-06-10 US disclosed
WO-2010063721-A1 1- (BIPHENYL-4-YLMETHYL) IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES AND THEIR USE AS CB2 RECEPTOR AGONISTS N.V. ORGANON (NL) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100144723-A1 1-(BIPHENYL-4-YLMETHYL)IMIDAZOLIDINE-2,4-DIONE OPRM1, OR10J3, OPRD1 LRRK2 3559/4885HRH3 32/4885KCNH2 123/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.